Novartis Licenses Worldwide Rights To Paratek's Broad-Spectrum Antibiotic
This article was originally published in The Pink Sheet Daily
Executive Summary
Clarified regulatory path for antibiotics may have helped produce potentially lucrative deal for the private biotech.
You may also be interested in...
FDA Updating Antibiotic Guidances, But Is It Too Late For Some Sponsors?
It was supposed to be a year with a wealth of novel antibiotics, but regulatory concerns turned 2008 from a year of banner antibiotic approvals into a sizeable crop of action letters. Now the delays are taking a serious toll, causing some sponsors to drastically restructure in the face of uncertain and evolving regulatory standards
Novartis Buys Protez For $100M
Another $300M due in potential milestone payments on Phase II antibiotic.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.